Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EG-007
- Development stage
- Phase 3
- Lead developer
- Shenzhen Eglin Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Injectable
01
Overview
EG-007 is an investigational injectable drug developed for the treatment of advanced endometrial cancer. It is being developed by Shenzhen Eglin Pharmaceutical (also known as Evergreen Therapeutics). The drug acts as an antagonist of the epidermal growth factor receptor (EGFR), targeting a protein implicated in both autoimmune diseases and certain cancers, where it is often overexpressed or dysregulated, leading to uncontrolled cell growth and immune dysfunction. EG-007 is designed to be used in combination with targeted therapies and anti-PD-1 antibody drugs to enhance tumor immunotherapy response rates, particularly by improving the tumor microenvironment—turning "cold tumors" into "hot tumors"—and increasing T-cell infiltration within tumor tissues. Preclinical studies have shown that this approach can significantly inhibit tumor growth compared to standard combinations or monotherapies. The drug has reached Phase III clinical trials for advanced endometrial cancer in both the Americas and Europe[2][3][5][6][7].
- Other names
- EG 007EG007EG-007
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on EG-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EG-007.